Eccogene Inc.

诚益生物开曼有限公司

Clinical-stage biotechnology company developing small-molecule drug candidates for cardiometabolic diseases, including MASH and obesity, with a pipeline of three clinical-stage and three preclinical programs; operates in China and the United States, listed in Hong Kong.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Connected or related major customers / suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Decline in revenue or profit
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Chapter 18A biotech